Key result
Sirolimus-eluting stents reduced the frequency of major adverse cardiac events compared to bare metal stents at 15 months in complex coronary artery lesions.
Why the study?
Do sirolimus-eluting stents reduce target vessel revascularisation and major adverse cardiac events in patients with symptomatic complex coronary artery disease compared to bare metal stents?
RCT (n=322)
randomly assigned
Do sirolimus-eluting stents reduce target vessel revascularisation and major adverse cardiac events in patients with symptomatic complex coronary artery disease compared to bare metal stents?
Sirolimus-eluting stents significantly reduce target vessel revascularization and MACE at 15 months compared to bare metal stents in complex coronary lesions, even after cessation of dual antiplatelet therapy.
Answers are grounded in this paper and cite their sources.
Supports sirolimus-eluting stents in complex lesions; confirms benefit persists after dual antiplatelet therapy cessation.
BACKGROUND: The randomised Stenting Coronary Arteries in Non-stress/benestent Disease (SCANDSTENT) trial reported considerably less angiographic restenosis after implantation of sirolimus-eluting stents (SES) vs bare metal stents (BMS) in patients with complex coronary lesions. The purpose of this study was to evaluate the clinical outcome after a majority of the SCANDSTENT patients had stopped the dual antiplatelet therapy. METHODS AND RESULTS: The SCANDSTENT trial randomly assigned 322 patients with symptomatic complex coronary artery disease (occlusions, bifurcations, ostial or angulated lesions) to receive SES or BMS. At 15 months after stent implantation, when 80% of the patients had stopped taking clopidogrel, six patients in the SES group and 10 in the BMS group had died or suffered a myocardial infarction (non significant [NS]). Compared with BMS, SES reduced the rate of target vessel revascularisation (TVR) from 33.1% to 5.6% (P<0.001) and the frequency of major adverse cardiac events from 35.7% to 8.6% (p<0.001). Definite stent thrombosis was observed in five patients in the BMS group, and two cases of probable and possible stent thrombosis were observed in the SES group (NS). One case of possible SES thrombosis occurred more than one year after stent implantation. CONCLUSIONS: Compared with BMS, SES markedly reduced the frequency of TVR and MACE within 15 months in SCANDSTENT patients with complex coronary artery lesions without development of delayed restenosis.
No takes yet. Share an insight, caveat, or question.
Helqvist et al. (2007) conducted an RCT in symptomatic complex coronary artery disease (n=322). Sirolimus-eluting stents (SES) vs. Bare metal stents (BMS) was evaluated on Major adverse cardiac events (p=<0.001). Sirolimus-eluting stents reduced the frequency of major adverse cardiac events compared to bare metal stents at 15 months in complex coronary artery lesions.
Synapse has enriched 10 related papers. Consider them for comparative context: